In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Harrow Health, with a price target of $64.00. The company’s shares closed last Friday at $37.48.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Knickerbocker is a 5-star analyst with an average return of 27.2% and a 61.46% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Harrow Health, Celcuity, and MiMedx Group.
In addition to Craig-Hallum, Harrow Health also received a Buy from Lake Street’s Brooks O’Neil in a report issued on October 6. However, on October 11, TR | OpenAI – 4o reiterated a Hold rating on Harrow Health (NASDAQ: HROW).
The company has a one-year high of $59.23 and a one-year low of $20.85. Currently, Harrow Health has an average volume of 694.8K.
Read More on HROW:
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
